PL2578229T3 - Zmniejszenie potencjalnego zagrożenia jatrogennego związanego z antygenami w szczepionce - Google Patents

Zmniejszenie potencjalnego zagrożenia jatrogennego związanego z antygenami w szczepionce

Info

Publication number
PL2578229T3
PL2578229T3 PL12193096T PL12193096T PL2578229T3 PL 2578229 T3 PL2578229 T3 PL 2578229T3 PL 12193096 T PL12193096 T PL 12193096T PL 12193096 T PL12193096 T PL 12193096T PL 2578229 T3 PL2578229 T3 PL 2578229T3
Authority
PL
Poland
Prior art keywords
vaccine antigens
risks associated
decreasing potential
pathogens
potential iatrogenic
Prior art date
Application number
PL12193096T
Other languages
English (en)
Inventor
Jens Peter Gregersen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35520177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2578229(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2578229T3 publication Critical patent/PL2578229T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
PL12193096T 2004-09-09 2005-09-09 Zmniejszenie potencjalnego zagrożenia jatrogennego związanego z antygenami w szczepionce PL2578229T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP04255471 2004-09-09
EP20100075310 EP2236155B1 (en) 2004-09-09 2005-09-09 Decreasing potential iatrogenic risks associated with influenza vaccines
EP12157945.2A EP2471551B1 (en) 2004-09-09 2005-09-09 Decreasing potential iatrogenic risks associated with influenza vaccines
EP20120193096 EP2578229B1 (en) 2004-09-09 2005-09-09 Decreasing potential iatrogenic risks associated with vaccine antigens
EP05795012A EP1789084B1 (en) 2004-09-09 2005-09-09 Decreasing potential iatrogenic risks associated with influenza vaccines

Publications (1)

Publication Number Publication Date
PL2578229T3 true PL2578229T3 (pl) 2014-01-31

Family

ID=35520177

Family Applications (4)

Application Number Title Priority Date Filing Date
PL05795012T PL1789084T3 (pl) 2004-09-09 2005-09-09 Zmniejszanie potencjału zagrożeń działaniami jatrogennymi związanymi ze szczepionkami przeciwko grypie
PL09075377T PL2179744T3 (pl) 2004-09-09 2005-09-09 Zmniejszanie potencjału zagrożeń działaniami jatrogennymi związanymi ze szczepionkami przeciwko grypie
PL12193096T PL2578229T3 (pl) 2004-09-09 2005-09-09 Zmniejszenie potencjalnego zagrożenia jatrogennego związanego z antygenami w szczepionce
PL10075310T PL2236155T3 (pl) 2004-09-09 2005-09-09 Zmniejszenie potencjalnego zagrożenia jatrogennego związanego ze szczepionkami przeciwko grypie

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL05795012T PL1789084T3 (pl) 2004-09-09 2005-09-09 Zmniejszanie potencjału zagrożeń działaniami jatrogennymi związanymi ze szczepionkami przeciwko grypie
PL09075377T PL2179744T3 (pl) 2004-09-09 2005-09-09 Zmniejszanie potencjału zagrożeń działaniami jatrogennymi związanymi ze szczepionkami przeciwko grypie

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL10075310T PL2236155T3 (pl) 2004-09-09 2005-09-09 Zmniejszenie potencjalnego zagrożenia jatrogennego związanego ze szczepionkami przeciwko grypie

Country Status (15)

Country Link
US (6) US8119337B2 (pl)
EP (5) EP2236155B1 (pl)
JP (7) JP2008512443A (pl)
AT (2) ATE489965T1 (pl)
CA (2) CA2579859C (pl)
CY (3) CY1111180T1 (pl)
DE (3) DE12193096T1 (pl)
DK (4) DK2236155T3 (pl)
ES (4) ES2357752T3 (pl)
HR (4) HRP20100673T1 (pl)
PL (4) PL1789084T3 (pl)
PT (4) PT2179744E (pl)
RS (3) RS51665B (pl)
SI (4) SI1789084T1 (pl)
WO (1) WO2006027698A1 (pl)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE489965T1 (de) 2004-09-09 2010-12-15 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
ES2310062B1 (es) 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
ES2525518T3 (es) 2005-11-01 2014-12-26 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
JP2009514844A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
CA2647985C (en) 2006-03-31 2014-12-30 Warf-Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP4585610A3 (en) 2006-09-11 2025-09-24 Seqirus UK Limited Making influenza virus vaccines without using eggs
WO2008059018A2 (en) * 2006-11-15 2008-05-22 Intervet International B.V. Vaccine for vaccinating felines and canines against influenza virus
PT2121011E (pt) 2006-12-06 2014-07-31 Novartis Ag Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
KR20100045437A (ko) 2007-06-27 2010-05-03 노파르티스 아게 첨가물이 적은 인플루엔자 백신
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
CA2741961A1 (en) 2008-11-05 2010-05-14 Glaxosmithkline Biologicals S.A. Novel method
EP3173097A3 (en) 2009-02-10 2017-07-12 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
EA201171032A1 (ru) 2009-02-10 2012-02-28 Новартис Аг Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
CA2752041A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
USH2283H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
EP2493912B1 (en) 2009-10-26 2020-07-29 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CA2797059A1 (en) * 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
CN103025350A (zh) 2010-05-21 2013-04-03 诺华有限公司 流感病毒的重配方法
WO2011151723A2 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens without lyophilization
CA2801151A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
GB201011502D0 (en) 2010-07-08 2010-08-25 Glaxosmithkline Biolog Sa Novel process
WO2012023044A1 (en) 2010-08-20 2012-02-23 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
AU2011300402B2 (en) 2010-09-07 2015-01-22 Novartis Ag Generic assays for detection of mammalian reovirus
AU2012221740B2 (en) * 2011-02-25 2016-11-17 Novartis Ag Exogenous internal positive control
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
EP2768528A1 (en) 2011-10-20 2014-08-27 Novartis AG Adjuvanted influenza b virus vaccines for pediatric priming
WO2013088367A1 (en) * 2011-12-12 2013-06-20 Novartis Ag Assay for influenza virus hemagglutinins
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
WO2015009743A1 (en) 2013-07-15 2015-01-22 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
EP3105311A1 (en) 2014-02-10 2016-12-21 Univercells NV System, apparatus and method for biomolecules production
RU2628800C2 (ru) * 2014-03-12 2017-08-22 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
KR102790570B1 (ko) 2015-07-07 2025-04-04 세퀴러스 유케이 리미티드 인플루엔자 효능 검정
US11197925B2 (en) 2016-02-19 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
KR20200117981A (ko) 2017-11-03 2020-10-14 다케다 백신즈 인코포레이티드 지카 백신 및 면역원성 조성물, 그리고 이를 이용하는 방법들
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
JP7655849B2 (ja) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
CN112912518A (zh) * 2018-10-15 2021-06-04 再生生物股份有限公司 用于测量复制缺陷型病毒载体和病毒的感染性的方法
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
BR112021019845A2 (pt) 2019-05-08 2022-02-15 Takeda Vaccines Inc Composições de vírus inativado e formulações de vacina contra zika
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
EP4061930A1 (en) 2019-11-18 2022-09-28 Seqirus Pty Ltd Method for producing reassortant influenza viruses
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
WO2022187230A2 (en) * 2021-03-01 2022-09-09 Iowa State University Research Foundation, Inc. Methods and compositions for detecting and producing porcine morbillivirus and immunogenic compositions thereof
CN114107392A (zh) * 2021-11-22 2022-03-01 昆明理工大学 一种cvb5病毒类病毒样颗粒的制备方法
EP4476329A1 (en) 2022-02-09 2024-12-18 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193991A (en) * 1978-12-20 1980-03-18 Cornell Research Foundation, Inc. Canine parvovirus vaccine
EP0261955A3 (en) * 1986-09-26 1989-06-07 E.I. Du Pont De Nemours And Company Process for immobilization of dna
US6284492B1 (en) * 1988-02-26 2001-09-04 Large Scale Biology Corporation Recombinant animal viral nucleic acids
NZ240369A (en) 1990-10-30 1993-09-27 Daiichi Seiyaku Co Muramyl dipeptide derivatives and vaccine compositions
JPH0813753B2 (ja) * 1992-05-22 1996-02-14 株式会社微生物化学研究所 牛伝染性鼻気管炎ウイルス感染症、牛ウイルス性下痢−粘膜病ウイルス感染症、パラインフルエンザ３型ウイルス感染症、牛ｒｓウイルス感染症および牛アデノ７型ウイルス感染症５種混合生ワクチン
IL103939A (en) * 1992-12-01 1996-09-12 Abic Ltd An anti-DBI vaccine in birds containing attenuated live DBI virus
CA2156525A1 (en) 1993-02-19 1994-09-01 Susan Dillon Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
DE4311580C1 (de) * 1993-04-12 1994-08-18 Werner Prof Dr Med Reutter Glycoproteine, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Mittel
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
CA2205015C (en) 1994-11-10 2003-04-08 Otfried Kistner Method for producing biologicals in protein-free culture
GB9500788D0 (en) 1995-01-16 1995-03-08 Medeva Holdings Bv Vaccine compositions
DE19612967A1 (de) * 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
JPH1175833A (ja) * 1997-06-23 1999-03-23 Chemo Sero Therapeut Res Inst トリレオウイルスの調製法
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
JP3795751B2 (ja) * 1997-12-11 2006-07-12 ユニバーシティ オブ サスカッチェワン ブタからの離乳後多全身系消耗症候群ウイルス
GB9804632D0 (en) * 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
DE10144903A1 (de) * 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
DK1499348T3 (en) * 2002-04-26 2015-01-05 Medimmune Llc PROCEDURE FOR PREPARING INFECTIOUS INFLUENZA B-VIRA IN CELL CULTURE
DE10221836A1 (de) * 2002-05-16 2003-12-04 Lohmann Animal Health Gmbh Attenuierung von Metapneumovirus
EP2287288B1 (en) * 2002-07-09 2012-11-07 Baxter International Inc. Animal protein free media for cultivation of cells
JP3957188B2 (ja) * 2002-10-25 2007-08-15 ▲あき▼夫 友田 抗ウィルス剤
WO2004066956A2 (en) 2003-01-30 2004-08-12 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
CN101410519B (zh) * 2003-04-25 2013-04-24 免疫医疗有限责任公司 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
ATE489965T1 (de) * 2004-09-09 2010-12-15 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
NZ582019A (en) 2007-06-14 2012-07-27 Univ Oklahoma State Vaccines containing canine parvovirus genetic variants

Also Published As

Publication number Publication date
EP2578229B1 (en) 2013-07-10
PL2179744T3 (pl) 2011-09-30
WO2006027698A1 (en) 2006-03-16
EP2471551A3 (en) 2012-11-14
JP2015205929A (ja) 2015-11-19
US20190078060A1 (en) 2019-03-14
EP2179744B1 (en) 2010-12-01
EP1789084A1 (en) 2007-05-30
CA2890962A1 (en) 2006-03-16
EP2236155A1 (en) 2010-10-06
HRP20130962T1 (hr) 2013-12-06
RS52400B (sr) 2013-02-28
SI2578229T1 (sl) 2013-10-30
ES2357747T3 (es) 2011-04-29
ES2386272T3 (es) 2012-08-16
PT2179744E (pt) 2011-03-09
RS51721B (sr) 2011-10-31
CY1111180T1 (el) 2015-06-11
CY1111208T1 (el) 2015-06-11
US20130122487A1 (en) 2013-05-16
ES2432655T3 (es) 2013-12-04
JP2008512443A (ja) 2008-04-24
HRP20110007T1 (hr) 2011-04-30
US9358280B2 (en) 2016-06-07
PL1789084T3 (pl) 2011-05-31
RS51665B (sr) 2011-10-31
US20120034600A1 (en) 2012-02-09
JP2011207911A (ja) 2011-10-20
JP2019210292A (ja) 2019-12-12
EP2471551B1 (en) 2017-02-01
HRP20120640T1 (hr) 2012-08-31
JP2012025784A (ja) 2012-02-09
DE602005025170D1 (de) 2011-01-13
ATE489965T1 (de) 2010-12-15
DK2179744T3 (da) 2011-01-31
DK1789084T3 (da) 2011-01-10
EP2471551A2 (en) 2012-07-04
SI1789084T1 (sl) 2011-03-31
US8460914B2 (en) 2013-06-11
US10155932B2 (en) 2018-12-18
DK2236155T3 (da) 2012-08-13
CA2579859A1 (en) 2006-03-16
JP2013100358A (ja) 2013-05-23
EP2236155B1 (en) 2012-05-16
CA2579859C (en) 2015-12-08
US8119337B2 (en) 2012-02-21
PT2578229E (pt) 2013-09-27
DK2578229T3 (da) 2013-10-07
EP2578229A1 (en) 2013-04-10
ES2357752T3 (es) 2011-04-29
PT1789084E (pt) 2011-02-22
PT2236155E (pt) 2012-07-19
EP1789084B1 (en) 2010-11-17
US20090081252A1 (en) 2009-03-26
DE12193096T1 (de) 2013-07-25
PL2236155T3 (pl) 2012-10-31
US10954493B2 (en) 2021-03-23
JP2017057209A (ja) 2017-03-23
HK1105364A1 (en) 2008-02-15
SI2236155T1 (sl) 2012-09-28
US9220768B2 (en) 2015-12-29
ATE488248T1 (de) 2010-12-15
SI2179744T1 (sl) 2011-04-29
CY1113225T1 (el) 2016-04-13
US20160251631A1 (en) 2016-09-01
HRP20100673T1 (hr) 2011-02-28
HK1144374A1 (en) 2011-02-18
US20130129782A1 (en) 2013-05-23
DE602005024827D1 (de) 2010-12-30
EP2179744A1 (en) 2010-04-28

Similar Documents

Publication Publication Date Title
SI2578229T1 (sl) Zmanjšanje potencialnih iatrogenih tveganj, povezanih z antigeni cepiv
MX2007008506A (es) Metodos y productos para genotipificacion in vitro.
TWI366882B (en) Handler, test-tray-transferring method used in the handler and packaged-chip-manufacturing process using the handler
WO2009108260A3 (en) Universal sample preparation system and use in an integrated analysis system
EP2038707A4 (en) OPTICALLY VARIABLE DEVICE HAVING A DIFFRACTION-BASED MICROOPTIC, METHOD OF CREATING THE SAME, AND ARTICLE EMPLOYING IT
GB2449772A (en) Large scale production of stem cells
TW200712688A (en) Light diffusing films, methods of making the same, and articles using the same
CA125780S (en) Air freshener device
WO2009070224A3 (en) Apparatus and method of a locality specific pre-hospital pediatric medical treatment
CL2011000913A1 (es) Vacuna combinada estable y completamente liquida que comprende antigenos difterico, tetanico, pertusico de celulas completas, y virus de poliomielitis y opcionalmente uno o mas antigenos seleccionados entre haemophilus influenzae y hepatitis; y proceso de fabricacion.
HK1201175A1 (en) Antigen presenting cancer vaccine with gamma interferon
WO2012118694A3 (en) Illumination systems with natural and artificial light inputs
GB2450599A (en) Automated culture of stem cells
EP1859673A4 (en) LIGHTING DEVICE AND PLANT CULTURE DEVICE EQUIPPED WITH LIGHTING DEVICE
WO2007062009A3 (en) Broccoli type having curds with detached florets
ATE443995T1 (de) Vorrichtung zur herstellung von lebensmitteln
PL2368572T3 (pl) Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
UA45034U (ru) Способ и.в. костик, в.г. выборного кранио-портретной идентификации личности
AU311285S (en) Air feshener device
CA124198S (en) Air freshener device
TR200900564U (tr) Telli çalgılar için plastik çakma perde.
WO2007095319A3 (en) Method of accelerated light stability testing and articles
AU306234S (en) Toddler style readybed
UA27827U (en) Dermatom with holder
AU301825S (en) Planting aid